Patients with ANCA-associated vasculitis (AAV) have a higher risk of mortality than the general population, especially those who are older or have impaired kidney function, a long-term outcome analysis study has found. Infections were the leading cause of death, with treatment complications, such as immunosuppression and blood vessel inflammation,…
An elderly woman was diagnosed with ANCA-associated vasculitis (AAV) after having an ischemic stroke, a condition wherein a blood clot cuts off blood supply to a part of the brain, a case study reported. It’s rare that AAV manifests in the central nervous system, which is made up of…
Nearly one-third of adults with ANCA-associated vasculitis (AAV) would choose plasma exchange regardless of varying risks of kidney failure and severe infection, according to an international study. One-fifth of patients would make that choice only in high-risk scenarios and one-sixth would reject that treatment in all scenarios, however.
The blood levels of several immune-related proteins are significantly altered in people with ANCA-associated vasculitis (AAV) up to five years before they develop symptoms when compared with matched healthy people, a study showed. Changes in these protein levels were found to be involved in inflammatory and metabolic pathways, and…
Rituximab is superior to cyclophosphamide at inducing disease remission after six months in people with granulomatosis with polyangiitis (GPA) — a type of ANCA-associated vasculitis (AAV) — according to a study in France. Similar findings were found for subgroups of GPA patients, such as those newly diagnosed with the disease…
Up to six months of treatment with rituximab led to disease remission in about two-thirds of Japanese patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), a study found. Further, people in Japan with these two types of ANCA-associated vasculitis (AAV) who were given rituximab as a…
Over the past year, ANCA Vasculitis News has brought you coverage of the latest developments in research related to ANCA-associated vasculitis (AAV). We look forward to continuing to bring you news about advances in research and treatment in the new year. Here we have compiled a list of the top…
Adding a low dose of cyclophosphamide to rituximab for remission induction was safe and more effective at preventing relapses in the first two years in people with severe ANCA-associated vasculitis (AAV) than rituximab alone, a new study shows. No significant benefit was observed in the combination treatment after five years.
Blood levels of the soluble forms of CD28 and TIM-3 — two receptor proteins involved in the regulation of immune responses — are significantly associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) activity, a study showed. The levels of these so-called immune checkpoint molecules were increased in people with active AAV…
Hepatitis E infection can be effectively managed in people with ANCA-associated vasculitis (AAV) by pausing immunosuppressive therapy, though patients may experience AAV flares during this pause, a new study shows. “Despite potent immunosuppression before infection, all patients cleared the virus after cessation of the immunosuppressant without additional anti-viral therapy.
Get regular updates to your inbox.